OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)
2018年10月24日 更新者:University of Florida
Hypertension (HTN) is a major risk factor for coronary heart disease (CHD), heart failure, kidney failure and stroke.
Disparities in HTN prevalence, treatment and control in the US have persisted for decades.
The prevalence of HTN is 44% among Blacks, which is among the highest rates in the world.
Those in ethnic/racial, rural, socioeconomically disadvantaged and other medically underserved populations are known to have the worst blood pressure (BP) control.
Awareness of, treatment for, and control of HTN is not optimal, and varies according to race, whereby BP is controlled in ~53% of non-Latino Whites, 42% of non-Latino Blacks and only 34% of Latinos.
Fundamental underlying differences in the pathophysiology contribute to HTN among different race groups.
The United States (US) 2014 HTN recommendations outline race-based pharmacotherapy care for HTN.
However, these recommendations use race-based population assumptions for Whites and Blacks only, do not include Latino ethnicity and have no accompanying guidelines or tools for successful implementation, particularly in rural primary care practices where disparate populations are common.
Moreover, these recommendations only apply to initial therapy and lack guidance on subsequent regimen selection.
The Optimizing Precision of HTN Care to Maximize BP Control Pilot (OPTI-BP Pilot), will directly address a long known and growing health disparity concern in the US which includes higher rates of death from CHD and stroke among Blacks and the poorest rates of HTN control among Latinos.
Utilizing a mixed methods approach, the overarching goal of OPTI-BP Pilot is to test, using a pragmatic trial design, a personalized, algorithmic-based HTN management approach focused on age, race, biomarker (plasma renin activity) and treatment factors.
The investigators hypothesize that implementation of a precision-based approach to the care of HTN in the community will improve BP reduction and ultimately reduce risk for CHD, stroke and death among those most affected by HTN.OPTI-BP Pilot is significant because it will utilize an innovative, systematic, precision-focused HTN management approach in an underserved, diverse population where BP control is currently suboptimal and lays the infrastructure groundwork for broad implementation across all areas of the US to minimize HTN related disparities and improve HTN outcomes.
研究概览
详细说明
The purpose of this research study is to develop pilot data to support a more precise way to treat high blood pressure based on an individual person's specific characteristics.
Information from a blood test called plasma renin activity will be entered into an on-line app that may more precisely determine which medication should be used to treat high blood pressure than random selection.
Renin is a substance in the body that is known to affect your blood pressure.
By measuring plasma renin activity, and using that to select a blood pressure lowering medication it may help to more precisely select medications based on how an individual will respond.
研究类型
介入性
注册 (实际的)
47
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Florida
-
Macclenny、Florida、美国、32063
- UF Health Family Medicine
-
Old Town、Florida、美国、32680
- UF Health Family Medicine - Old Town
-
Tallahassee、Florida、美国、32307
- Tallahassee Memorial Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- untreated HTN (systolic BP ≥ 140 or diastolic BP ≥ 90 mm Hg while taking no anti-HTN drugs)
- treated, uncontrolled HTN (systolic BP ≥ 140 or diastolic BP ≥ 90 mm Hg while taking one or more anti-HTN drug)
- provide voluntary, written informed consent
- willing to comply with requirements of the study including provision of a blood sample for local laboratory determined PRA.
Exclusion Criteria:
- treated and controlled HTN (systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg)
- systolic BP ≥ 180 mm Hg or diastolic BP ≥ 110 mm Hg
- secondary forms of HTN or any active, unstable disease process requiring new diagnostic and therapeutic plans
- any life-threatening illness
- history of alcohol or drug abuse in the past 5 years
- mental illness or personality disorder that might interfere with adherence to study protocol
- end-stage renal disease and progressive chronic kidney disease with serum creatinine >2.5 mg/dl
- intolerance to two or more classes of anti-HTN medications
- pregnant women or breast feeding women
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:非随机化
- 介入模型:阶乘赋值
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:High Blood Pressure Consented
Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples.
Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
|
The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
其他名称:
Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
|
|
无干预:De-identified historical data
De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications.
The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
BP control
大体时间:6 months
|
We will measure BP control in patients who underwent PRA testing.
BP control in the PRA tested patients will be compared with historic control patients who did not undergo PRA testing.
|
6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年6月18日
初级完成 (实际的)
2018年6月30日
研究完成 (实际的)
2018年6月30日
研究注册日期
首次提交
2016年6月23日
首先提交符合 QC 标准的
2016年6月23日
首次发布 (估计)
2016年6月27日
研究记录更新
最后更新发布 (实际的)
2018年10月25日
上次提交的符合 QC 标准的更新
2018年10月24日
最后验证
2018年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.